title: Inhibitors of Angiogenesis.
abstract: Angiogenesis plays a pivotal role in malignant, ischemic, inflammatory, infectious and immune disorders. The increasing molecular understanding of angiogenic processes fostered the development of strategies to induce or inhibit angiogenesis for therapeutic purposes. Here, we focus on anti-angiogenic therapies, which represent a standard of care in the treatment of different cancer types and in neovascular age-related macular degeneration. Specifically, strategies related to the blockade of angiogenic proteins and receptors will be outlined covering both preclinical and clinical aspects. Finally, examples of gene therapy based anti-angiogenic approaches are presented.
authors.affiliation: Institute of Experimental Hematology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany. buening.hildegard@mh-hannover.de.
authors.forename: H
authors.initials: H
authors.lastname: Büning
authors.affiliation: Universitäres Krebszentrum (UCCL), Universitätsklinikum Leipzig, Liebigstraße 20, 04103, Leipzig, Germany.
authors.forename: U T
authors.initials: UT
authors.lastname: Hacker
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000818:Animals; D006801:Humans; D009369:Neoplasms / Q000098:blood supply / Q000188:drug therapy*; D009389:Neovascularization, Pathologic / Q000517:prevention & control*; D057135:Wet Macular Degeneration / Q000188:drug therapy*
chemical_list: D020533:Angiogenesis Inhibitors
keywords: Angiogenesis; Antibodies; Gene therapy; VEGF; Vascular maturation